Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02137785 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
A Phase 3 study, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 269
- Enrollment target
NCT02137785: Completed Phase 3 study, sponsored by DUSA Pharmaceuticals.
NCT02137785 is a Phase 3 study that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 269 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02137785, a Phase 3 study, has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 269 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratoses on the upper arms and hands
Primary Outcome
proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area
Interventions
- DRUG Aminolevulinic Acid (ALA)
- DRUG Topical Solution Vehicle
- DEVICE Blue Light Photodynamic Therapy Illuminator (BLU-U)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
What the finished NCT02137785 record still lists
NCT02137785 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Aminolevulinic Acid (ALA) is the first listed.
NCT02137785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02137785 about?
NCT02137785 is a clinical study titled "Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities". The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratoses on the upper arms and hands
What is the current status of trial NCT02137785?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 269 participants. The study started on 2014-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02137785?
The interventions under investigation include: Aminolevulinic Acid (ALA) (DRUG), Topical Solution Vehicle (DRUG), Blue Light Photodynamic Therapy Illuminator (BLU-U) (DEVICE).
Who is sponsoring clinical trial NCT02137785?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02137785's enrollment target sits among peer trials
269 1220th of 2000 higher than 779 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia